Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

This is a prospective, single-arm, multicenter, Phase IV study of 1564 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque psoriasis who have converted from other biologics. To explore the efficacy of difficult-to-treat area, patient satisfaction and patient-reported outcomes (PRO).

NCT Number	NCT06779097
Lead Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions	Moderate to Severe Plaque Psoriasis
Enrollment	1,564 participants
Start Date	2025-02
Primary Completion	2027-03 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2025-01-16